Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Prader-Willi Syndrome (PWS) - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 53 | Code: MRS - 3079

 

Global Markets Directs, Prader-Willi Syndrome (PWS) Pipeline Review, H2 2014, provides an overview of the Prader-Willi Syndrome (PWS)s therapeutic pipeline.


This report provides comprehensive information on the therapeutic development for Prader-Willi Syndrome (PWS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prader-Willi Syndrome (PWS) and special features on late-stage and discontinued projects.


Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope


The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Prader-Willi Syndrome (PWS) and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Prader-Willi Syndrome (PWS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Prader-Willi Syndrome (PWS) pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products


Reasons to buy


Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents


Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Prader-Willi Syndrome (PWS) Overview 6
Therapeutics Development 7
Pipeline Products for Prader-Willi Syndrome (PWS) - Overview 7
Pipeline Products for Prader-Willi Syndrome (PWS) - Comparative Analysis 8
Prader-Willi Syndrome (PWS) - Therapeutics under Development by Companies 9
Prader-Willi Syndrome (PWS) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Prader-Willi Syndrome (PWS) - Products under Development by Companies 13
Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development 14
Chong Kun Dang Pharmaceutical Corp. 14
Essentialis, Inc. 15
Ferring International Center S.A. 16
LG Life Sciences, Ltd. 17
P2D Bioscience 18
Pfizer Inc. 19
Rhythm Pharmaceuticals 20
Prader-Willi Syndrome (PWS) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
beloranib - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
betahistine hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
diazoxide choline CR - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
FE-992097 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NOX-B11 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
setmelanotide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
somatropin SR - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Prader-Willi Syndrome (PWS) - Recent Pipeline Updates 41
Prader-Willi Syndrome (PWS) - Product Development Milestones 46
Featured News & Press Releases 46
Nov 14, 2014: Essentialis To Present Clinical Update At The Annual Research Conference Of The Foundation For Prader-Willi Research 46
Oct 01, 2014: Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome 46
Jul 23, 2014: Essentialis Secures Foundation for Prader-Willi Research Grant to Help Advance DCCR in the Treatment of Prader-Willi Syndrome 47
Jul 10, 2014: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome 47
Jun 27, 2014: Essentialis Announces the Dosing of the First Patient in a Clinical Study of DCCR in Prader-Willi Syndrome 48
Jun 17, 2014: Essentialis Announces the Grant of its First Japanese Patent Which Provides Extensive Protection to DCCR in the Treatment of Prader-Willi Syndrome 49
May 28, 2014: Essentialis Obtains Orphan Drug Designation from FDA for DCCR in the Treatment of Prader-Willi Syndrome 49
Jan 15, 2014: Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 50

Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

 

List of Tables
 

Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2014 7
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Prader-Willi Syndrome (PWS) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 14
Prader-Willi Syndrome (PWS) - Pipeline by Essentialis, Inc., H2 2014 15
Prader-Willi Syndrome (PWS) - Pipeline by Ferring International Center S.A., H2 2014 16
Prader-Willi Syndrome (PWS) - Pipeline by LG Life Sciences, Ltd., H2 2014 17
Prader-Willi Syndrome (PWS) - Pipeline by P2D Bioscience, H2 2014 18
Prader-Willi Syndrome (PWS) - Pipeline by Pfizer Inc., H2 2014 19
Prader-Willi Syndrome (PWS) - Pipeline by Rhythm Pharmaceuticals, H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Prader-Willi Syndrome (PWS) Therapeutics - Recent Pipeline Updates, H2 2014 41

 

List of Figures
 

Number of Products under Development for Prader-Willi Syndrome (PWS), H2 2014 7
Number of Products under Development for Prader-Willi Syndrome (PWS) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Targets, H2 2014 22
Number of Products by Stage and Top 10 Targets, H2 2014 23
Number of Products by Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 25
Number of Products by Top 10 Routes of Administration, H2 2014 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 27
Number of Products by Top 10 Molecule Types, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 29

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing